Angiotensin II type 1 receptor antagonism mediates uncoupling protein 2-driven oxidative stress and ameliorates pancreatic islet β-cell function in young type 2 diabetic mice

Antioxidants and Redox Signaling

Volumn 9, Issue 7, 2007, Pages 869-878

  Kwan, Yi Chu ^a   Leung, Po Sing ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; COMPLEMENTARY DNA; INSULIN; LOSARTAN; MESSENGER RNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCOUPLING PROTEIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SUBUNIT; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; INSULIN RELEASE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; INSULIN; ION CHANNELS; ISLETS OF LANGERHANS; LOSARTAN; MICE; MICE, INBRED C57BL; MICE, OBESE; MITOCHONDRIAL PROTEINS; MODELS, BIOLOGICAL; NADPH OXIDASE; OBESITY; OXIDATIVE STRESS; RANDOM ALLOCATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

ANIMALIA; MUS;

EID: 34250333856     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2007.1590     Document Type: Article

References (42)

1. Anderson JW, Kendall CW, and Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 22: 331-339, 2003.
2. Beckman JS and Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad and ugly. Am J Physiol 271: C1424-C1437, 1996.
3. Blanc J, ves-Guerra MC, Esposito B, Rousset S, Gourdy P, Ricquier D, Tedgui A, Miroux B, and Mallat Z. Protective role of uncoupling protein 2 in atherosclerosis. Circulation 107: 388-390, 2003.
4. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, and Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52 : 102-110, 2003.
5. Carlsson PO, Berne C, and Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 41: 127-133, 1998.
6. Chan CB, Saleh MC, Koshkin V, and Wheeler MB. Uncoupling protein 2 and islet function. Diabetes 53(suppl 1): S136-S142, 2004.
7. Chan CB, MacDonald PE, Saleh MC, Johns DC, Marban E, and Wheeler MB. Overexpression of uncoupling protein 2 inhibits glucose-stimulated insulin secretion from rat islets. Diabetes 48: 1482-1486, 1999.
8. Chu KY, Lau T, Carlsson PO, and Leung PS. Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes 55: 367-374, 2006.
9. Collins P, Jones C, Choudhury S, Damelin L, and Hodgson H. Increased expression of uncoupling protein 2 in HepG2 cells attenuates oxidative damage and apoptosis. Liver Int 25: 880-887, 2005.
10. Donath MY and Halban PA. Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications. Diabetologia 47: 581-589, 2004.
11. Evans JL, Goldfine ID, Maddux BA, and Grodsky GM. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes 52: 1-8, 2003.
12. Fridlyand LE and Philipson LH. Does the glucose-dependent insulin secretion mechanism itself cause oxidative stress in pancreatic beta-cells? Diabetes 53: 1942-1948, 2004.
13. Green K, Brand MD, and Murphy MP. Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. Diabetes 53(suppl 1): S110-S118, 2004.
14. Griendling KK, Minieri CA, and Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74: 1141-1148, 1994.
15. Inoguchi T and Nawata H. NAD(P)H oxidase activation: a potential target mechanism for diabetic vascular complications, progressive beta-cell dysfunction and metabolic syndrome. Curr Drug Targets 6: 495-501, 2005.
16. Krauss S, Zhang CY, Scorrano L, Dalgaard LT, St-Pierre J, Grey ST, and Lowell BB. Superoxide-mediated activation of uncoupling protein 2 causes pancreatic beta cell dysfunction. J Clin Invest 112: 1831-1842, 2003.
17. Lameloise N, Muzzin P, Prentki M, and Assimacopoulos-Jeannet F. Uncoupling protein 2: a possible link between fatty acid excess and impaired glucose-induced insulin secretion? Diabetes 50: 803-809, 2001.
18. Lau T, Carlsson PO, and Leung PS. Evidence for a local angiotensin-gencrating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia 47: 240-248, 2004.
19. Leung PS and Carlsson PO. Pancreatic islet renin angiotensin system: its novel roles in islet function and in diabetes mellitus. Pancreas 30: 293-298, 2005.
20. Li LX, Skorpen F, Egeberg K, Jorgensen IH, and Grill V. Uncoupling protein-2 participates in cellular defense against oxidative stress in clonal beta-cells. Biochem Biophys Res Commun 282: 273-277, 2001.
21. Lowell BB and Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science 307: 384-387, 2005.
22. Lupi R, Del GS, Bugliani M, Boggi U, Mosca F, Torri S, Del PS, and Marchetti P. The direct effects of the angiotensin-converting enzyme inhibitors, zofenoprilat and enalaprilat, on isolated human pancreatic islets. Eur J Endocrinol 154: 355-361, 2006.
23. Marselli L, Dotta F, Piro S, Santangelo C, Masini M, Lupi R, Realacci M, del GS, Mosca F, Boggi U, Purrello F, Navalesi R, and Marchetti P. Th2 cytokines have a partial, direct protective effect on the function and survival of isolated human islets exposed to combined proinflammatory and Th1 cytokines. J Clin Endocrinol Metab 86: 4974-4978, 2001.
24. Nakayama M, Inoguchi T, Sonta T, Maeda Y, Sasaki S, Sawada F, Tsubouchi H, Sonoda N, Kobayashi K, Sumimoto H, and Nawata H. Increased expression of NAD(P)H oxidase in islets of animal models of type 2 diabetes and its improvement by an AT1 receptor-antagonist. Biochem Biophys Res Commun 332: 927-933, 2005.
25. Oliveira HR, Verlengia R, Carvalho CR, Britto LR, Curi R, and Carpinelli AR. Pancreatic beta-cells express phagocyte-like NAD(P)H oxidase. Diabetes 52: 1457-1463, 2003.
26. O'Rahilly S. Uncoupling protein, 2: adiposity angel and diabetes devil? Nat Med 7: 770-772, 2001.
27. Paul M, Poyan MA, and Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 86: 747-803, 2006.
28. Porte D Jr. Banting lecture 1990: beta-cells in type II diabetes mellitus. Diabetes 40: 166-180, 1991.
29. Prentki M and Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest 116: 1802-1812, 2006.
30. Ramracheya RD, Muller DS, Wu Y, Whitehouse BJ, Huang GC, Amiel SA, Karallicddc J, Viberti G, Jones PM, and Persaud SJ. Direct regulation of insulin secretion by angiotensin II in human islets of Langerhans. Diabetologia 49: 321-331, 2006.
31. Reaven GM. Banting lecture 1988: Role of insulin resistance in human disease. Diabetes 37: 1595-1607, 1988.
32. Sakuraba H, Mizukami H, Yagihashi N, Wada R, Hanyu C, and Yagihashi S. Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese type II diabetic patients. Diabetologia 45: 85-96, 2002.
33. Schrauwen P and Hesselink MK. Oxidative capacity, lipotoxicity, and mitochondrial damage in type 2 diabetes. Diabetes 53: 1412-1417, 2004.
34. Shao J, Iwashita N, Ikeda F, Ogihara T, Uchida T, Shimizu T, Uchino H, Hirose T, Kawamori R, and Watada H. Beneficial effects of candesartan, an angiotensin II type 1 receptor blocker, on beta-cell function and morphology in db/db mice. Biochem Biophys Res Commun 344: 1224-1233, 2006.
35. Stump CS, Hamilton MT, and Sowers JR. Effect of antihypertensive agents on the development of type 2 diabetes mellitus. Mayo Clin Proc 81: 796-806, 2006.
36. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, and Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol 35: 881-900, 2003.
37. Tiedge M, Lortz S, Drinkgern J, and Lenzen S. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes 46: 1733-1742, 1997.
38. Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC, and Cooper ME. Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat. Diabetes 53: 989-997, 2004.
39. 2 receptor antagonists and their effects on changes in the severity of pancreatitis. Int J Biochem Cell Biol 36: 330-339, 2004.
40. Vincent AM, Olzmann JA, Brownlee M, Sivitz WI, and Russell JW. Uncoupling proteins prevent glucose-induced neuronal oxidative stress and programmed cell death. Diabetes 53: 726-734, 2004.
41. Zhang CY, Baffy G, Perret P, Krauss S, Peroni O, Grujic D, Hagen T, Vidal-Puig AJ, Boss O, Kim YB, Zheng XX, Wheeler MB, Shulman GI, Chan CB, and Lowell BB. Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell 105: 745-755, 2001.
42. Zhang Y, Bloem LJ, Yu L, Estridge TB, Iversen PW, McDonald CE, Schrcmenti JP, Wang X, Vlahos CJ, and Wang J. Protein kinase C beta II activation induces angiotensin converting enzyme expression in neonatal rat cardiomyocytes. Cardiovasc Res 57: 139-146, 2003.